Why Axsome Therapeutics, Inc. (AXSM) Stock Fell 5.8% on Oct 13, 2026
What happened
Axsome Therapeutics extended a multi-day losing streak as part of a sector-wide pullback in growth-oriented biotech stocks amid macro headwinds—specifically surging oil prices and rising Treasury yields pressuring risk-on equities. AXSM fell 4.95% to $157.79 intraday on volume 1.49x the 120-minute average, contributing to a cumulative drop of roughly 14% over an 11-session stretch through mid-October 2026.
Axsome's third-quarter 2026 earnings release on November 2, 2026; consensus EPS estimate is −$0.55. Monitor Auvelity prescription-volume trends and any guidance revisions as key catalysts for sentiment reversal.
Frequently asked questions
Why did Axsome Therapeutics, Inc. (AXSM) stock fall on Oct 13, 2026?
Axsome Therapeutics extended a multi-day losing streak as part of a sector-wide pullback in growth-oriented biotech stocks amid macro headwinds—specifically surging oil prices and rising Treasury yields pressuring risk-on equities. AXSM fell 4.95% to $157.79 intraday on volume 1.49x the 120-minute average, contributing to a cumulative drop of roughly 14% over an 11-session stretch through mid-October 2026.
How much did AXSM stock fall on Oct 13, 2026?
AXSM fell 5.8% during the Oct 13, 2026 trading session.